Patents by Inventor Zahra Shahrokh

Zahra Shahrokh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110091414
    Abstract: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.
    Type: Application
    Filed: October 12, 2010
    Publication date: April 21, 2011
    Inventors: Gaozhong Zhu, Vinh T. Nguyen, Kris Lowe, Zahra Shahrokh
  • Publication number: 20110054153
    Abstract: The present invention relates generally to Apo2L/TRAIL purification involving crystallization.
    Type: Application
    Filed: May 10, 2006
    Publication date: March 3, 2011
    Inventors: Heather Flores, Tanya Lin, Timothy Matthews, Roger Pai, Zahra Shahrokh
  • Patent number: 7855066
    Abstract: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: December 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Sarah Hymowitz, Robert F. Kelley, Iphigenia Koumenis, Woon-Lam Susan Leung, Mark O'Connell, Roger Pai, Zahra Shahrokh, Laura Simmons
  • Patent number: 7842668
    Abstract: The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: November 30, 2010
    Assignee: Genentech, Inc.
    Inventors: Heather Flores, Tanya P. Lin, Timothy C. Matthews, Roger Pai, Zahra Shahrokh
  • Patent number: 7842789
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: November 30, 2010
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Publication number: 20100291060
    Abstract: The invention relates, in part, to improved methods of administering ?-galactosidase A for the treatment of ?-galactosidase A deficiencies including Fabry disease.
    Type: Application
    Filed: August 28, 2008
    Publication date: November 18, 2010
    Applicant: Shire Human Genetic Therapies, Inc
    Inventors: Lisa Marie Sturk, Justin C. Lamsa, Michael W. Heartlein, Vinh Nguyen, Katherine D. Taylor, Zahra Shahrokh
  • Patent number: 7833766
    Abstract: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: November 16, 2010
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Gaozhong Zhu, Vinh T. Nguyen, Kris Lowe, Zahra Shahrokh
  • Patent number: 7741285
    Abstract: The present invention relates generally to Apo2L/TRAIL purification involving crystallization.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Heather Flores, Tanya P. Lin, Timothy C. Matthews, Roger Pai, Zahra Shahrokh
  • Patent number: 7741282
    Abstract: The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Tanya P. Lin, Zahra Shahrokh, Heather Flores, Roger Pai, Timothy C. Matthews
  • Publication number: 20090098147
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Application
    Filed: November 12, 2008
    Publication date: April 16, 2009
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Patent number: 7507405
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: March 24, 2009
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Publication number: 20070197439
    Abstract: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.
    Type: Application
    Filed: February 6, 2007
    Publication date: August 23, 2007
    Inventors: Gaozhong Zhu, Vinh Nguyen, Kris Lowe, Zahra Shahrokh
  • Publication number: 20070161564
    Abstract: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.
    Type: Application
    Filed: November 22, 2006
    Publication date: July 12, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Sarah Hymowitz, Robert Kelley, Iphigenia Koumenis, Woon-Lam Leung, Mark O'Connell, Roger Pai, Zahra Shahrokh, Laura Simmons
  • Patent number: 7214776
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: May 8, 2007
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Publication number: 20070048219
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Application
    Filed: September 28, 2006
    Publication date: March 1, 2007
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Patent number: 7122636
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: October 17, 2006
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Publication number: 20060083683
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Application
    Filed: October 25, 2005
    Publication date: April 20, 2006
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Patent number: 7005504
    Abstract: Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: February 28, 2006
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Leonard Presta, Zahra Shahrokh, Gerardo Zapata
  • Publication number: 20060009387
    Abstract: The present invention relates generally to Apo2L/TRAIL purification involving crystallization.
    Type: Application
    Filed: May 24, 2005
    Publication date: January 12, 2006
    Applicant: GENENTECH, INC.
    Inventors: Heather Flores, Tanya Lin, Timothy Matthews, Roger Pai, Zahra Shahrokh
  • Publication number: 20050158316
    Abstract: A method of treating hemorrhagic shock with a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.8 to about 5.5, a surfactant and a polyol.
    Type: Application
    Filed: March 10, 2005
    Publication date: July 21, 2005
    Applicant: Genentech, Inc.
    Inventors: Xanthe Lam, James Oeswein, Boonsri Ongpipattanakul, Zahra Shahrokh, Sharon Wang, Robert Weissburg, Rita Wong